文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

氧负荷试验对接受体外膜氧合的心源性休克患者的预后价值

[Prognostic value of oxygen challenge test for patients with cardiogenic shock receiving extracorporeal membrane oxygenation].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2017-01-01
一句话结论心源性休克患者接受V-A ECMO后6小时行10分钟氧负荷试验,OCT10≥70.0 mmHg和OCI≥0.68与60天生存率更高相关,且为60天死亡的独立危险因素。

该单中心回顾性分析纳入2012年6月至2017年5月南京医科大学附属无锡市人民医院ICU收治的78例心源性休克接受V-A ECMO患者,最终67例纳入分析(生存组31例、死亡组36例)。ECMO启动后6小时行10分钟氧负荷试验,记录经皮氧分压(PtO2)、10分钟OCT值(OCT10)和氧负荷指数(OCI)。死亡组APACHE II评分、SOFA评分、IABP使用比例更高,PtO2、OCT10、OCI更低,ECMO和机械通气时间更长。OCT10预测60天死亡的AUC为0.866±0.042(95%CI 0.760-0.937),OCI的AUC为0.829±0.051(95%CI 0.717-0.910);OCT10截断值≥70.0 mmHg(敏感度91.67%、特异度67.74%),OCI截断值≥0.68(敏感度88.68%、特异度71.58%)。高OCT10组60天累积生存率显著高于低OCT10组[58.06%(18/31)vs. 36.11%(13/36),χ²=5.425,P=0.020],高OCI组生存率显著高于低OCI组[55.17%(16/29)vs. 39.47%(15/38),χ²=5.119,P=0.024]。多因素Logistic回归显示OCT10(OR=0.883,95%CI 0.791-0.965,P=0.006)和OCI(OR=0.011,95%CI 0.

要点

  • 心源性休克V-A ECMO启动后6小时行10分钟氧负荷试验,OCT10截断值≥70.0 mmHg预测60天死亡,敏感度91.67%、特异度67.74%。
  • OCI截断值≥0.68预测60天死亡,敏感度88.68%、特异度71.58%。
  • 高OCT10组60天累积生存率58.06%(18/31)显著高于低OCT10组36.11%(13/36),P=0.020。
  • 高OCI组60天累积生存率55.17%(16/29)显著高于低OCI组39.47%(15/38),P=0.024。
  • 多因素Logistic回归显示OCT10(OR=0.883,95%CI 0.791-0.965)和OCI(OR=0.011,95%CI 0.001-0.087)为60天死亡的独立危险因素。

适用人群与场景

  • 2012年6月至2017年5月南京医科大学附属无锡市人民医院ICU收治的心源性休克接受V-A ECMO患者,最终67例纳入分析。

诊断标准与关键阈值

  • OCT10预测60天死亡的截断值为≥70.0 mmHg,敏感度91.67%、特异度67.74%。
  • OCI预测60天死亡的截断值为≥0.68,敏感度88.68%、特异度71.58%。

处置流程与药物剂量

  • ECMO启动后6小时通过经皮血氧测定实施10分钟氧负荷试验,记录PtO2、OCT10和OCI。

研究设计与关键结果

  • 单中心回顾性分析,最终纳入67例心源性休克接受V-A ECMO患者,生存组31例、死亡组36例。
  • 死亡组较生存组APACHE II评分、SOFA评分、IABP使用比例更高,PtO2、OCT10、OCI更低,ECMO和机械通气时间更长;性别、年龄、原发病、LVEF、MAP、呼吸机设置、血管活性药剂量、动脉血气结果两组无显著差异。
  • OCT10预测60天死亡的AUC为0.866±0.042(95%CI 0.760-0.937),OCI的AUC为0.829±0.051(95%CI 0.717-0.910),APACHE II评分的AUC为0.860±0.043(95%CI 0.754-0.933),SOFA评分的AUC为0.821±0.049(95%CI 0.708-0.904),均P<0.01。
  • 高OCT10组60天累积生存率58.06%(18/31)显著高于低OCT10组36.11%(13/36),χ²=5.425,P=0.020。
  • 高OCI组60天累积生存率55.17%(16/29)显著高于低OCI组39.47%(15/38),χ²=5.119,P=0.024。
  • 多因素Logistic回归显示OCT10(OR=0.883,95%CI 0.791-0.965,P=0.006)和OCI(OR=0.011,95%CI 0.001-0.087,P=0.005)为60天死亡的独立危险因素。

证据类型、等级与局限

  • 证据类型:单中心回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为OCT可预测接受ECMO的心源性休克患者的预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the prognostic value of oxygen challenge test (OCT) for patients with cardiogenic shock receiving extracorporeal membrane oxygenation (ECMO).

METHODS: A retrospective analysis was conducted. Seventy-eight patients diagnosed with cardiogenic shock receiving veno-arterial (V-A) ECMO admitted to Department of intensive care unit (ICU) of Wuxi People's Hospital Affiliated to Nanjing Medical University from June 2012 to May 2017 were enrolled. Ten-minute OCT was implemented by transcutaneous oximetry at 6 hours after ECMO initiation. The basic data of patients (gender, age, primary disease); the acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, left ventricular ejection fraction (LVEF), mean arterial pressure (MAP) at the start of ECMO treatment; arterial blood gas analysis index, dose of vasoactive agents, transcutaneous oxygen pressure (PtO2), 10-minute OCT value (OCT10), oxygen challenge index (OCI) at 6 hours after ECMO initiation; and the ECMO support time, duration of mechanical ventilation and its parameters, and application of intra-aortic balloon pump (IABP) within 60 days were recorded. Patients were divided into the survival group and the death group according to their 60-day mortality status, and the differences between the two groups were compared. Receiver operating characteristic curve (ROC) analysis was used to analyze the prognostic value of OCT10 and OCI. According to the best boundary value of OCT10 and OCI, Kaplan-Meier survival curve was drawn and the 60-day cumulative survival rate was compared. The risk factors affecting prognosis were analyzed by multivariate Logistic regression.

RESULTS: Sixty-seven patients were finally enrolled in the study, with 31 in the survival group and 36 in the death group. Compared with the survival group, APACHE II score, SOFA score, use of IABP in death group were higher, PtO2, OCT10 and OCI were lower, and duration of ECMO and ventilation were longer, but there was no significant difference in gender, age, primary disease, LVEF, MAP, ventilator settings, dose of vasoactive agents, or results of arterial blood gas between the two groups. OCT10, OCI, APACHE II score and SOFA score were predictive values for 60-day deaths, and the area under ROC curve (AUC) of OCT10 was 0.866±0.042 [95% confidence interval (95%CI) = 0.760-0.937], the AUC of OCI was 0.829±0.051 (95%CI = 0.717-0.910), the AUC of APACHE II score was 0.860±0.043 (95%CI = 0.754-0.933), and the AUC of SOFA score was 0.821±0.049 (95%CI = 0.708-0.904) (all P < 0.01). The cut-off point for OCT10 was ≥70.0 mmHg (1 mmHg = 0.133 kPa) with the sensitivity of 91.67% and the specificity of 67.74%. The cut-off point for OCI was ≥0.68 with the sensitivity of 88.68% and the specificity of 71.58%. According to the cut-off point for OCT10 or OCI, the 60-day cumulative survival rate of patients with high OCT10 was significantly higher than that of low OCT10 [58.06% (18/31) vs. 36.11% (13/36), χ2 = 5.425, P = 0.020]; the survival rate in high OCI group was significantly higher than that in low OCI group [55.17% (16/29) vs. 39.47% (15/38), χ2 = 5.119, P = 0.024]. It was shown by multivariate Logistic regression that OCT10 [odds ratio (OR) = 0.883, 95%CI = 0.791-0.965, P = 0.006] and OCI (OR = 0.011, 95%CI = 0.001-0.087, P = 0.005) were independent risk factors for 60-day mortality.

CONCLUSIONS: OCT could predict the prognosis of patients with cardiogenic shock receiving ECMO.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Dong L, Zhang X, Liang F, et al. [Prognostic value of oxygen challenge test for patients with cardiogenic shock receiving extracorporeal membrane oxygenation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 29216944. doi:10.3760/cma.j.issn.2095-4352.2017.12.010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。